Indication
Oligometastasis
8 clinical trials
17 products
7 drugs
Clinical trial
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)Status: Recruiting, Estimated PCD: 2025-07-01
Product
GoserelinProduct
ADTProduct
Degarelix & RelugolixProduct
ADT + DocetaxelProduct
ADT + ApalutamideProduct
ADT + EnzalutamideClinical trial
a Randomized Trial for OLIGo Metastases Breast cAncer With or Without Metastasis-dIrected TherapyStatus: Recruiting, Estimated PCD: 2026-11-08
Product
Systemic therapyClinical trial
A Randomized Trial Comparing Early Local Chemoradiation Therapy +/- Surgery Versus Systemic Therapy for Patients With Esophageal or Gastric Cancer With OligometastasesStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
CisplatinDrug
fluorouracilDrug
UTD1Clinical trial
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET StudyStatus: Not yet recruiting, Estimated PCD: 2031-01-01
Product
EnzalutamideProduct
DarolutamideProduct
ApalutamideDrug
DocetaxelProduct
Lutetium-PSMAClinical trial
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Phase 2 TrialStatus: Recruiting, Estimated PCD: 2024-02-01
Drug
PD-1 antibodyClinical trial
A Study Comparing Intermittent Androgen Depriving Therapy With Or Without Salvage High-Dose Intensity Modulation Radiotherapy (IG-IMRT)To Oligometastatic Pelvic Lymph Nodes In Biochemically-relapsing Prostate Cancer Patients.Status: Active (not recruiting), Estimated PCD: 2026-06-01
Product
IADTClinical trial
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: a Randomized Phase II Trial (DART)Status: Recruiting, Estimated PCD: 2026-02-12
Clinical trial
a New Spark in Treating Oligorecurrent Prostate Cancer: Adding Systemic Treatment to Stereotactic Body Radiotherapy or Metastasectomy: Key to Long-lasting Event-free Survival?Status: Recruiting, Estimated PCD: 2027-04-25
Drug
goserelin